536 related articles for article (PubMed ID: 27238081)
21. Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer.
Almeida-Rios D; Graça I; Vieira FQ; Ramalho-Carvalho J; Pereira-Silva E; Martins AT; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Oncotarget; 2016 Aug; 7(33):53018-53028. PubMed ID: 27323813
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
Nikhil K; Haymour HS; Kamra M; Shah K
Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589
[TBL] [Abstract][Full Text] [Related]
23. [The mechanisms of prostate cancer progression through androgen receptor].
Goto Y; Sakamoto S; Ichikawa T
Nihon Rinsho; 2016 Jan; 74(1):55-9. PubMed ID: 26793880
[TBL] [Abstract][Full Text] [Related]
24. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
25. Are androgen receptor variants a substitute for the full-length receptor?
Lu J; Van der Steen T; Tindall DJ
Nat Rev Urol; 2015 Mar; 12(3):137-44. PubMed ID: 25666893
[TBL] [Abstract][Full Text] [Related]
26. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance.
Cai Z; Wu Y; Li Y; Ren J; Wang L
Aging (Albany NY); 2018 Dec; 10(12):3702-3712. PubMed ID: 30513511
[TBL] [Abstract][Full Text] [Related]
27. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH
Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800
[TBL] [Abstract][Full Text] [Related]
28. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.
Parolia A; Venalainen E; Xue H; Mather R; Lin D; Wu R; Pucci P; Rogalski J; Evans JR; Feng F; Collins CC; Wang Y; Crea F
Mol Oncol; 2019 May; 13(5):1121-1136. PubMed ID: 30776192
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
30. [The concept and mechanisms of castration-resistant prostate cancer].
Naito S; Shiota M
Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
[TBL] [Abstract][Full Text] [Related]
31. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
32. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation.
Yu Y; Zhang Y; Guan W; Huang T; Kang J; Sheng X; Qi J
Mol Cancer Res; 2014 Jun; 12(6):830-42. PubMed ID: 24574517
[TBL] [Abstract][Full Text] [Related]
34. Arrestin2 modulates androgen receptor activation.
Purayil HT; Zhang Y; Dey A; Gersey Z; Espana-Serrano L; Daaka Y
Oncogene; 2015 Jun; 34(24):3144-51. PubMed ID: 25109335
[TBL] [Abstract][Full Text] [Related]
35. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
Li N; Chen M; Truong S; Yan C; Buttyan R
Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
[TBL] [Abstract][Full Text] [Related]
36. Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer.
McClurg UL; Harle VJ; Nabbi A; Batalha-Pereira A; Walker S; Coffey K; Gaughan L; McCracken SR; Robson CN
Oncotarget; 2015 Nov; 6(35):37724-36. PubMed ID: 26462181
[TBL] [Abstract][Full Text] [Related]
37. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
38. PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.
Wang J; Zhang H; Zhang X; Wang P; Wang H; Huang F; Zhou C; Zhou J; Li S
Oncotarget; 2016 Dec; 7(49):81377-81388. PubMed ID: 27835608
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
40. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
